Source: StemCells, Inc.
Date: June 18, 2007
Summary:
StemCells, Inc. (NASDAQ: STEM) today announced that the Phase I clinical trial of its proprietary HuCNS-SC(TM) product candidate (purified human neural stem cells) has successfully completed enrollment of the low-dose cohort and will proceed to the high-dose cohort.
